Post-traumatic epilepsy: current and emerging treatment options

Jerzy P Szaflarski1,3
Yara Nazzal1,3
Laura E Dreer2

1Department of Neurology, 2Department of Ophthalmology, 3UAB Epilepsy Center, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: Traumatic brain injury (TBI) leads to many undesired problems and complications, including immediate and long-term seizures/epilepsy, changes in mood, behavioral, and personality problems, cognitive and motor deficits, movement disorders, and sleep problems. Clinicians involved in the treatment of patients with acute TBI need to be aware of a number of issues, including the incidence and prevalence of early seizures and post-traumatic epilepsy (PTE), comorbidities associated with seizures and anticonvulsant therapies, and factors that can contribute to their emergence. While strong scientific evidence for early seizure prevention in TBI is available for phenytoin (PHT), other antiepileptic medications, eg, levetiracetam (LEV), are also being utilized in clinical settings. The use of PHT has its drawbacks, including cognitive side effects and effects on function recovery. Rates of recovery after TBI are expected to plateau after a certain period of time. Nevertheless, some patients continue to improve while others deteriorate without any clear contributing factors. Thus, one must ask, ‘Are there any actions that can be taken to decrease the chance of post-traumatic seizures and epilepsy while minimizing potential short- and long-term effects of anticonvulsants?’ While the answer is ‘probably,’ more evidence is needed to replace PHT with LEV on a permanent basis. Some have proposed studies to address this issue, while others look toward different options, including other anticonvulsants (eg, perampanel or other AMPA antagonists), or less established treatments (eg, ketamine). In this review, we focus on a comparison of the use of PHT versus LEV in the acute TBI setting and summarize the clinical aspects of seizure prevention in humans with appropriate, but general, references to the animal literature.

Keywords: traumatic brain injury, TBI, seizures, epilepsy, seizure prevention, cognition, EEG, antiepileptic drugs

Introduction

In about 6% of patients with epilepsy, seizures are thought to be the result of previous head trauma; frequently, seizures in these patients are difficult to control with standard antiepileptic drugs (AEDs).1 The presence of early and late seizures has significant effect on subsequent outcomes, including medication use, quality of life, employment, and psychosocial adjustment. In these patients, the original insult is frequently identified from the history, but the severity of the injury may be difficult to judge. Based on studies conducted over the last several decades, patients who have suffered moderate or severe traumatic brain injury (TBI) are typically placed on an AED right after the initial trauma, usually phenytoin (PHT), but more recently also on levetiracetam (LEV), in order to alter the progression of epileptogenesis to late seizures and epilepsy. If seizures are not present in the first 7 days after trauma, the AED is weaned, with an expectation that seizures will not occur in the future. Since the concept of seizure and epilepsy prevention after TBI is well established, it is incumbent upon us to determine...
not only which factors, when present or absent in the latent period (time between trauma and late seizures), are important for initiating and completing the cascade of events that eventually lead to seizure occurrence, but also how we can modulate or abort this process so that seizures never occur. It is imperative to develop strategies that change the process of epileptogenesis while concurrently decreasing the chance of the development of unwanted comorbidities (eg, worsening of cognitive deficits related to TBI and AEDs). Finally, it is important to be mindful of the financial implications – PHT was found to be more cost effective than LEV in a setting of seizure prevention after TBI, but this gap may be disappearing with the costs becoming similar in the recent years, and this calculation did not take into account the effects of these treatments on long-term costs.²

In this review focusing on the comparison between PHT and LEV, we summarize the clinical aspects of seizure prevention in humans, with appropriate but general references to animal literature, and provide brief discussion of potential new developments.

Epidemiology of early vs late post-traumatic epilepsy

The epidemiology of post-traumatic epilepsy (PTE) is well established. Early seizures are defined as seizures occurring in the first 7 days of trauma, while PTE is defined as seizures occurring after this period.³ The incidence of early seizures after TBI is reported to be between 2.6% and 16.3%, with the differences being dependent mainly on study design.³,⁴ At least in univariate analysis, the presence of early seizures predisposes the development of late PTE; overall early seizures are thought of as an epiphenomenon and a result of an acute injury, with their presence not necessarily equating with the development of late PTE.³⁴ In fact, the pathophysiologic mechanisms leading to early post-traumatic seizures are not clearly understood, and multiple factors are thought to play a role, including interruption of the blood–brain barrier, presence of hemorrhage, and injury-related excitotoxicity.⁵–⁸

The reported incidence of late PTE is dependent, in part, on the study design. In a population-based cohort of 2,747 patients with TBI, the risk of PTE after a severe TBI was 7.1% at 1 year and 11.5% at 5 years. After moderate brain injury, the risk of PTE was 0.7% at 1 year and 1.6% at 5 years. The risk of PTE was not increased after mild head injury defined as head injury without skull fracture with either loss of consciousness or posttraumatic amnesia lasting less than 30 minutes.⁹ In the trial of PHT versus placebo for seizure prevention after TBI, 86% of patients who developed seizures did so within 2 years of the incident trauma.¹⁰,¹¹ Finally, in a large population-based study, the risk of PTE was relatively small and non-significantly elevated after mild injury (1.5 after adjusting for all other factors) and increased after moderate (2.9 times) and severe (17.0 times) TBI.¹² Salazar et al¹² reported the overall occurrence of PTE in 53% of Vietnam veterans who had suffered from various penetrating head wounds and who required neurosurgical intervention. More than 90% of PTE presented within the first 10 years of trauma; occurrence of PTE significantly correlated with multiple risk factors, including brain volume loss, the presence of metal fragment, hematoma, and residual neurological deficits.¹² These authors estimated the risk of developing epilepsy within the first year of penetrating head trauma to be 580 times higher than in a population not at risk. Finally, a recent cross-sectional study investigated PTE in a cohort of the veterans of the Afghanistan and Iraq conflicts to show age-adjusted prevalence of 6.1 per 1,000, with odds of developing epilepsy related to previous TBI of 18.77 (95% confidence interval [CI] 9.21–38.23) when compared with veterans who did not suffer TBI.¹³ Thus, the picture painted by these epidemiological studies is that the more severe the injury the more likely the person with TBI is to develop PTE; that more than 80% of PTE starts within 2 years of TBI; that presence of skull fracture, penetrating injury, and neurological deficits predispose to the development of PTE; and that age at the time of injury may be a factor in the development of PTE.

Seizure and epilepsy prevention after TBI

The idea behind the use of AEDs in the immediate post-injury period is based on the desire to prevent the development of late PTE as a long-term, and at times debilitating, comorbidity, ie, finding a time window for an intervention that will stop the process of epileptogenesis.⁷ However, it needs to be recognized that besides seizures and PTE, TBI is frequently followed by various immediate and long-term deficits.⁷,¹⁴,¹⁵ These include, among others, focal neurological deficits, cognitive problems, changes in mood (eg, depression), movement disorders, sleep disorders, and behavioral problems. Some of these deficits may improve or resolve relatively quickly after the injury while some of them may worsen after initial improvement.¹⁶,¹⁷ Further, information on how treatment with AEDs in the acute phase influences long-term outcomes, including the development of PTE, is relatively sparse. Prophylaxis against seizures is a part of standard therapy in the acute phase of moderate or severe TBI. As per guidelines from multiple organizations, including the Brain Trauma
Foundation and the American Academy of Neurology, the most commonly used prophylactic agent is PHT, which is typically administered for the first 7 days after TBI. But while prophylaxis with PHT decreases the incidence of early posttraumatic seizures from 14.2% to 3.6% when compared with placebo, this treatment has not been shown to decrease the risk of late posttraumatic seizures and epilepsy.

PHT has numerous side effects and drug interactions and exhibits complex nonlinear pharmacokinetics that necessitate therapeutic drug monitoring; its steady state concentrations are often not achievable within the first 7 days of therapy. Further, maintaining therapeutic levels of PHT is challenging in patients with TBI because the levels are affected by multiple factors frequently present in TBI patients, including decreased protein binding, variable gastrointestinal absorption, and increased drug clearance. Further, while PHT reduces seizures, concerns have been raised that it may also adversely affect cognitive recovery, at least in some forms of brain injury. A recent study investigated the outcomes of patients treated with PHT for seizure prophylaxis after TBI compared with matched patients who, based on clinical judgment, had not received PHT prophylaxis. While no differences were observed in the incidence of seizures between groups, patients treated with PHT showed worse outcomes, including Glasgow Outcomes Scale and modified Ranking Scale (both \( P < 0.05 \)). Multiple caveats to this study need to be considered, including small sample size, lack of randomization, and the choice of treatment versus no treatment based on personal preferences of the providers rather than predetermined schemes.

An alternative to PHT may be LEV, an agent recently added to the seizure-prevention armamentarium. The availability of this AED is especially relevant for critically ill patients with TBI because of the ease of administration, low rate of adverse events, and potential for improved outcomes. A recently reported small-scale, single-blinded randomized trial suggests the use of LEV rather than PHT in acute TBI may be associated with better 6-month cognitive outcomes. While promising, these preliminary single-blinded data are not sufficient to warrant a change in clinical practice. More studies are needed to determine its long-term impact after injury. To date, no prospective, double-blind randomized controlled trials (RCTs) have been conducted to compare the effects of LEV versus PHT on neurocognitive and seizure outcomes among individuals with moderate or severe TBI.

Several ‘older’ AEDs have been evaluated for the treatment of early post-traumatic seizures with a goal of targeting the development of late PTE. These include PHT, valproate (VPA), and carbamazepine (CBZ). The available data on PHT, VPA, and CBZ were reviewed in a recent ‘practice parameter’ and are discussed here only briefly. For PHT, evidence from pooled studies indicates a significantly lower risk of early post-traumatic seizures in patients who receive PHT for seizure prophylaxis when compared with placebo (relative risk 0.37) and no reduction in late post-traumatic seizures (relative risk 1.05). Oral (via feeding tube) CBZ, given immediately after TBI and continued for 18–24 months, was used for seizure prophylaxis in one quasi-randomized study in which outcomes were compared with a placebo group. Patients treated with CBZ showed a significantly lower probability of early and late post-traumatic seizures, but the results of this study are confounded by the fact that patients were treated initially with intravenous PHT until they were able to receive oral CBZ. Finally, one study evaluated VPA for seizure prevention after TBI to show similar incidences of seizures in patients randomized to 1 week of PHT, 1 month of VPA, or 6 months of VPA (\( P = 0.19 \)) and a trend toward higher mortality with VPA (\( P = 0.07 \)); the effects of both AEDs on neuropsychological health were similar. Based on these results the use of VPA for seizure prevention cannot be recommended. Overall, this is surprising because VPA has been shown to be neuroprotective in several models of acute central nervous system injury (for review, see Chen et al). Thus, the available studies provide level 1 evidence for the short-term use of PHT for seizure prevention in the setting of acute brain injury, while the use of VPA and CBZ in this setting is questionable. Currently, there is no class I evidence that the ‘older’ AEDs should be used for long-term prevention of PTE.

The results of the previous studies put into perspective the proposed use of LEV in the setting of acute TBI. In animal studies, LEV has been shown to have several mechanisms of action, including modulation of neuropeptide Y receptors and neuronal Ca++ channels, threshold elevation for L-type Ca++ channel neuronal currents, modulation of neurotransmitter release via binding to the synaptic vesicle protein 2A (inhibition of Ca++ release from intracellular stores), and opposition of the negative modulation of gammabutyric acid (GABA)- and glycine-gated currents. These mechanisms of action could explain the unique antiepileptogenic activity of LEV, including neuroprotection, seizure prevention, and improved cognitive outcomes of LEV use in animal models of brain injury, and support its use for seizure prevention in moderate and severe TBI. To offer more detail, LEV has recently been shown to be...
neuroprotective in a rodent model of controlled cortical impact (CCI) and subarachnoid hemorrhage (effect that has not been observed with PHT); administration of LEV but not PHT improved functional outcomes. Another rodent study showed that 20 days of LEV treatment following CCI, when compared with placebo, promoted neuronal sparing, decreased the volume of injury, and reduced release of pro-inflammatory interleukin (IL)-1β. Finally, LEV alone or in combination with diazepam decreased seizure-related hippocampal neurodegeneration. Next is the issue of seizure prevention – the process of epileptogenesis (transformation of normal brain tissue into one capable of spontaneously generating seizures) can be prevented or aborted by LEV. While it is recognized that LEV is not antiepileptogenic in all animal models, recent studies have shown that LEV aborts hyperexcitability in hippocampal neurons after status epilepticus, and that it exerts antiepileptogenic effects in spontaneously epileptic rats. Relevant to the discussion is the effect of LEV on cognition – rodents administered LEV beginning 1 day after CCI for 20 days showed improved motor and cognitive functions, including balance (beam walking), spatial learning and memory (maze navigation), and exploration.

In the setting of TBI, some of the issues related to the use of AEDs revolve around the potential effects of these medications on EEG. This is because a growing body of evidence supports the notion that interictal epileptiform discharges (IEDs) and/or seizures result in long-term cognitive deficits. In fact, IEDs have been shown not only to affect cognitive performance, including alertness and speed of processing, at the moment of their occurrence but also to contribute to negative long-term cognitive outcomes such as decreased educational achievement. The negative effect of IEDs on cognition may be comparable to the effects of brief seizures. There is also evidence that AEDs such as LEV may positively affect the EEG by suppressing IEDs and by improving the overall background of the EEG; these effects are not observed with PHT. In addition to IEDs, the other common EEG abnormalities observed in TBI are seizures. Because of the abundance of EEG abnormalities, it can be difficult to separate the short- and long-term effects of the injury alone from the associated seizures. Animal studies indicate that brain trauma causes global, in addition to focal, abnormalities, and that these abnormalities are most pronounced in the most vulnerable areas – ie, hippocampus. Further, animal model research has documented the relationship between TBI and seizures and the positive impact of seizure medication treatments on improving neurobehavioral outcomes in TBI. Recently, human studies have shown that seizures in patients with TBI disproportionately contribute to hippocampal atrophy, that seizures cause increases in intracranial pressure and increased lactate/pyruvate ratio, both of which have deleterious effects on post-TBI recovery, and that patients with seizures related to any type of brain injury, when compared with matched patients without injury, have poorer outcomes and higher mortality. Thus, there is little doubt that seizures and/or IEDs have a negative influence on recovery after TBI.

The next issue that requires consideration is cognitive performance. It is well recognized that most AEDs have negative effects on cognition. The archetypical AED for these effects is topiramate, which has been shown to negatively affect cognitive performance in healthy subjects and in patients with epilepsy. The effects of PHT and LEV on cognition are not as pronounced and are likely different. PHT has been noted to have significant long-term effects on cognition, including negative effects on concentration, memory, visuomotor functions and mental speed; these effects may be dose related. Some studies have shown detrimental effects of PHT on cognitive performance when compared with other AEDs (eg, carbamazepine), with these negative effects improving after PHT discontinuation. On the other hand, LEV as a member of the pyrrolidine class of drugs, may improve cognition via enhancing higher integrative mechanisms of the brain. In fact, LEV has been shown to improve a range of cognitive abilities, including visual short-term memory, working memory, motor functions, psychomotor speed and concentration, and fluid intelligence. Comparative data are scarce – while one small comparative study showed no difference in cognitive outcomes in patients with epilepsy treated with LEV versus PHT, the authors recognized the lack of power to detect such a difference (n=10; participants taking concurrently various AEDs including PHT, CBZ, and/or VPA). To date, systematic direct comparisons in patients with epilepsy have not been performed, but some studies have indicated improvements in cognition when patients were either transitioned to or treated with LEV monotherapy. Similar improvements in cognitive performance of patients with epilepsy while treated with PHT have not been observed or reported. Finally, individuals with existing cognitive weaknesses (as in TBI) may benefit most from LEV and, in fact, a blinded study showed that recent memory improved most in patients with poor baseline scores. In contrast to the relative paucity of epilepsy data, a recent study of patients with brain tumors after resection showed that the neurocognitive
performance of patients treated with LEV was equal to or better than that of matched patients not treated with any AEDs and better than the performance of patients treated with PHT or VPA; in contrast to treatment with PHT, treatments with LEV or VPA were not associated with additional cognitive deficits. 

Another study in an animal model of Alzheimer’s disease showed that treatment with LEV improved cognitive performance via reduction of epileptiform discharges and reversal of hippocampal remodeling, behavioral abnormalities, synaptic dysfunction, and deficits in learning and memory. In addition to the effects described above, negative effects on EEG and cognitive performance have been observed in patients treated with PHT, especially at high doses and levels.

Based on a single RCT, PHT has been shown to have a negative effect on cognitive outcomes in patients with TBI. A recent study in subarachnoid hemorrhage showed that these effects may be dependent on the dose and treatment duration with PHT. These findings have led some to question the use of PHT in the setting of TBI. Newer AEDs, specifically LEV, may be better tolerated and have less adverse impact on the plasticity of recovery. Studies have shown that patients with various etiologies of brain injury, including TBI, experience better outcomes on a variety of measures (adverse effects, Modified Rankin Scale, Glasgow Outcomes Scale) when treated with LEV compared with PHT. To that end, one small retrospective non-randomized study in TBI evaluated cognitive performance and showed a trend toward improved outcomes among patients treated with LEV versus PHT (P=0.08). Finally, a single-blinded RCT has shown better Glasgow Outcome Scale and modified Rankin Scale outcomes in patients with moderate or severe TBI who were treated with LEV versus PHT.

Evidence for seizures after brain injury and the effects of PHT vs LEV

The likelihood of early seizures is related to the severity of brain injury. Further, as indicated above, there is some evidence that early seizures may translate into the development of long-term epilepsy, though the data from population-based studies are not entirely in support of this notion. The factors that lead to the establishment of the long-term epileptic state are not fully understood, but there is considerable evidence to suggest that seizures in the acute period may drive changes that will result in the development of PTE. Early use of AEDs may prevent these changes from occurring, reverse the process of early epileptogenesis related to injury, and prevent chronic epilepsy.

As mentioned previously, because of the short-term risk of seizures and long-term risks of epilepsy, patients with TBI are typically treated with AEDs for 7 days. The most frequently used AED in this setting is PHT. However, PHT was also found to be associated with substantial liver toxicity, hypotension, hematologic abnormalities, drug interactions, and sedation, all of which are problematic in critically ill patients. Finally, as indicated above, studies suggest that the use of PHT in this setting is associated with adverse cognitive effects, negative effects on post-TBI recovery, and even negative effects on brain anatomy.

The incidence of acute post-TBI seizures depends on whether seizures are reported based on clinical (~2%) or continuous EEG (cEEG) (~22%) criteria. Recently, cEEG monitoring has been used to determine the incidence of early seizures in critically ill patients. In TBI studies that included cEEG, the incidence of early seizures was found to range from 16% to 22%, with the vast majority of seizures being non-convulsive (52%–100%); approximately 95% of the identified seizures occurred within 72 hours of trauma. Further, it has been shown that the use of cEEG leads to treatment changes in more than 50% of the monitored patients. These findings support the empiric use of AEDs and of the cEEG in the critical care setting. Data from a recent randomized and blinded study support the notion that cEEG performed in the first 72 hours after TBI contributes to outcome prediction, with alpha variability being the most important predictive factor. Thus, suppressing or eliminating IEDs and seizures should result in improved cognitive performance, while knowledge of the cEEG characteristics can contribute to the overall long-term prediction of outcomes.

Patients with moderate or severe TBI admitted to neuroscience intensive care units are at increased risk for seizures due to their underlying neurological injury. Early-onset seizures in patients with TBI greatly increase the incidence of subsequent seizures/epilepsy and the chance of secondary harm, including increased intracranial pressure, hypoxia, physical injury, and mortality. Any of these complications may adversely affect the cognitive and neurological status of patients with TBI, and worsen their clinical outcomes. Further, the presence of seizures or status epilepticus in patients with TBI, similar to other acute neurological insults such as stroke, is associated with increased mortality. Thus, seizure prevention is critical for the long-term outcomes of patients with brain injury, and cEEG may be a valuable biomarker of initial epileptogenicity and for long-term outcomes.
Thus, to summarize, while there is no level 1 evidence that LEV may be equivalent to or better than PHT when used for seizure prevention in patients with TBI, there is a substantial body of evidence that the use of LEV should be considered in this setting, and further investigations are needed. Finally, prophylaxis of late PTE is neither indicated nor recommended. The data from observational studies and RCTs provide no evidence to support such use of AEDs.

**Future directions**

Clinical post-TBI recovery occurs over periods of months and years, and so does the process of epileptogenesis. In fact, epileptogenesis may progress in spite of clinical improvements and in parallel with them. So, the goal of seizure prevention (clinical and research) should be to abort the process of epileptogenesis in addition to short-term seizure prevention, while not negatively affecting the process of post-TBI recovery. Multiple possible avenues need to be further investigated.

At least theoretical grounds exist for the use of several existing and potential AEDs for seizure and PTE prevention in TBI. The possibilities include the use of anticonvulsants that exert activity against AMPA receptors, including lacosamide and topiramate. In fact, in models of acute brain injury other than TBI, topiramate in the setting of therapeutic hypothermia has already been shown to be neuroprotective.

Further, talampanel and perampanel, two novel AEDs that are known AMPA antagonists, have also been shown to be antiepileptogenic; talampanel is also known to be neuroprotective. Since another AMPA-receptor antagonist, NS1209, with a mechanism of action similar to that of perampanel (also a selective AMPA-receptor antagonist that decreases hyperexcitability by targeting glutamate activity at post-synaptic AMPA receptors) has already been shown to be neuroprotective and effective in various animal models of epilepsy, including status epilepticus, we can probably assume all AEDs with this mechanism of action have similar properties. Other potential developments may include lacosamide because of its relative ease of use and the availability of intravenous and oral forms that are easily exchangeable, and the fact that this AED has been shown to be potentially anti-epileptogenic in animal models of kindling.

Finally, ketamine, a N-methyl D-aspartate (NMDA) receptor antagonist, has recently gained attention as a possible treatment of refractory status epilepticus; this drug is known to decrease or prevent NMDA-receptor up-regulation and thus decrease the possibility of neurotoxicity via glutamate cascade. This is especially important in view of a recent study that used CCI as a model of TBI to show that cortical excitability and glutamatergic signaling were altered following injury. The results of this study suggest that specific cortical neuronal microcircuits may initiate and facilitate the spread of epileptiform activity following TBI and increased glutamatergic signaling due to loss of GABAergic control, which may provide a mechanism by which TBI can give rise to PTE.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


